Lighter You Review: "Science-Backed Peptides" That the Site Never Names
Lighter You sells a programme called Peptides & Longevity on a single line of copy — "[s]cience-backed peptides for energy, recovery, and healthy aging" — and never tells you which peptides. Not on the card, not in the FAQ, not anywhere in the 495,437 characters of code that draw its website. The molecules are knowable, but only by following the button: its own redirect map sends that programme to an intake called "Metabolic and Cellular Optimization", whose eligibility rules name sermorelin, NAD, glutathione, methylene blue, B12-MIC and L-carnitine one by one. That intake turns out to be the most careful thing this company has built. It is also where the same button sends women who click "Women's Health".
Dispenses
Compounded only
Evidence
Phase 3 trials
Pharmacy
Not named
FDA letter
None found
By Grant Delaney, Research Editor·
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.lighteryou.co. A link is not a recommendation to take anything.
Provenance
What Lighter You actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Compounded (503A)4 products
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Peptides & Longevity programme — sermorelin component — The programme card reads "Starting at $145". No ongoing rate, billing cycle or dose tier is published anywhere on the site.
Peptides & Longevity programme — NAD+ component — Covered by the same "Starting at $145" card; no per-molecule price is published.
Peptides & Longevity programme — glutathione component — Covered by the same "Starting at $145" card.
Weight Loss programme (MACRO-Dosing MWL) and Microdosing programme — "Starting at $169" on both the Weight Loss and Microdosing cards, against a site-wide banner advertising "Starting at $99". Neither figure is described as introductory or ongoing.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
Sermorelin · cmpd
No human trial
NAD+ · cmpd
No human trial
Glutathione · cmpd
No human trial
Semaglutide and tirzepatide · cmpd
Phase 3 trials
1
Products with a human trial
Out of 4 reviewed here.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Lighter You’s own page, with the page it came from. Grading a paraphrase would prove nothing.
As of August 2026, a PubMed search for sermorelin filtered to the randomised-controlled-trial publication type returned 19 records, the most recent published in 2005 — a study of a PEG-conjugated GHRH analogue measuring growth hormone stimulation in healthy young and elderly subjects. Every one of the 19 measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None measures energy, recovery or healthy aging as an outcome in healthy adults. A parallel search of ClinicalTrials.gov for sermorelin as an intervention returned 27 studies.
"Science-backed" is the entire claim, it is four words long, and it is made for a formulary the buyer cannot see. Sermorelin is a growth-hormone-releasing hormone analogue and it does stimulate pituitary GH release — a real mechanism, which is why it was used as a diagnostic agent. The literature attached to it stopped producing randomised trials in 2005, and none of those trials measured energy or recovery in healthy adults. A claim that names no molecule cannot be checked by the person paying for it, which is the deeper problem here: the reader has no way to know what "science-backed" is supposed to refer to.1,2
Peptides & Longevity programme — NAD+ component
No trial supports this claim
“Science-backed peptides for energy, recovery, and healthy aging.”
As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" in the title or abstract, combined with an injected route (subcutaneous, injection or intravenous) and filtered to the randomised-controlled-trial publication type, returned exactly one record: a 2026 placebo-controlled trial of NAD+ in heart failure caused by ischaemic cardiomyopathy. Removing the route filter raises the count to 70, none of which tests an injected preparation for energy or healthy aging. A parallel ClinicalTrials.gov search for NAD+ as an intervention returned 261 studies, across conditions including lupus, mild cognitive impairment and hepatitis C.
NAD+ is a coenzyme, it does decline with age, and none of that is disputed. The claim on sale is that an injected preparation delivers "energy" and "healthy aging", and the randomised evidence for the injected route is a single trial in heart-failure patients. Note that NAD+ is not a peptide — it is a dinucleotide — so the heading "Science-backed peptides" is not even the right category for the largest component of the programme it describes.3
As of August 2026, a PubMed search for glutathione combined with subcutaneous and filtered to the randomised-controlled-trial publication type returned nine records, and reading them matters more than counting them. Four are veterinary — dairy cattle and dairy goats given selenium or trace-element supplements. In the remaining five, glutathione is a blood marker that was measured rather than a drug that was injected: a schistosomiasis vaccine trial, a methyl-B12 trial in children with autism, a vegetarian-diet trial, an allergen-immunotherapy study and a study of heparin after surgery. None tests injected glutathione as an intervention in healthy adults.
Glutathione is genuinely the principal intracellular antioxidant and it genuinely draws down under oxidative load. What has not been shown is that injecting it produces "energy" or "recovery" in a healthy adult, and the randomised literature for the injected route contains nothing in that population. Glutathione is a tripeptide, so unlike NAD+ it at least belongs under the word "peptides" — but the buyer is never told it is in the programme.4
Weight Loss programme (MACRO-Dosing MWL) and Microdosing programme
Claim reaches past the trials
“Through our trusted pharmacy partners, we offer a range of prescription wellness therapies, including GLP-1 medications such as tirzepatide and semaglutide, targeted peptide therapies, and medications for men's and women's health. Every treatment plan is prescribed by a licensed healthcare provider based on your individual health needs and clinical evaluation.”
Semaglutide and tirzepatide · Compounded (503A) · read August 2026
Phase 3 trials
NCT03548935STEP 1 — Phase 3, completed, n=1,961. Tested the approved once-weekly semaglutide 2.4 mg product in adults with overweight or obesity. No compounded preparation has been through a registered trial.
NCT04184622SURMOUNT-1 — Phase 3, completed, n=2,539. Tested the approved tirzepatide product in adults with obesity or overweight.
The FAQ answer itself is accurate and appropriately hedged, and the footer carries a correct compounding disclaimer. What overstates sits a few hundred pixels away: an interactive slider on the same page that, for a 220 lb starting weight, returns "Weight you could lose: 48 lbs" — roughly 22% of body weight — with no drug named, no dose, no time period and no indication that it describes a trial result rather than an expectation. The molecules underneath have genuine phase 3 evidence; the number the slider produces is presented as a personal projection with nothing attached to it.5,6,7
Dispensing chain
Who actually fills your prescription
Pharmacy not named
No pharmacy is named. The word "pharmacy" occurs twice in Lighter You's entire published bundle, in the phrases "a partner pharmacy" and "our trusted pharmacy partners", and the how-it-works step says only that "the prescription is sent to a partner pharmacy for fulfillment." The clinical side is disclosed slightly better, though never on Lighter You's own pages: the footer links its telehealth consent to openloophealth.com, and the intake at shop.lighteryou.co runs on the same white-label platform, so OpenLoop is identifiable as the telehealth partner by following the link rather than by being told. The more useful discovery is what sits behind the buttons. The `/go` redirect chunk maps each product card to an intake product ID, and those IDs resolve through the platform's own API to named templates: weight loss to "MACRO-Dosing MWL Initial Intake", microdosing to "MICRO-Dosing GLP-1/GIP Initial Intake", men's health to "ED Initial Intake", and both peptides AND women's health to "Metabolic and Cellular Optimization Initial Intake". That last mapping is a fault worth naming: a patient clicking "Women's Health" is sent to the NAD+ and sermorelin questionnaire. All four templates were read on 2026-08-07.
Nothing at all, and the absence was measured rather than assumed. Lighter You's whole site is served from a client bundle of 495,437 characters, read on August 7, 2026. Across it, the strings "tested", "sterile", "USP", "potency", "purity", "certificate of analysis", "COA", "503A" and "503B" occur ZERO times. There is no testing page, no named standard, no potency tolerance, no lot report, and no statement of whether the preparations come from a 503A pharmacy or a 503B outsourcing facility — a distinction that determines what inspection regime applies to the vial. What Lighter You does publish is a correct regulatory disclaimer: "Compounded drug products are not FDA approved. FDA does not evaluate compounded products for safety, effectiveness, or quality." That describes what nobody has checked rather than what anybody has. Pages carry a LegitScript seal served under certificate id 51449551; LegitScript's public checker is reCAPTCHA-gated and returned no certification record when queried on August 7, 2026, so the seal is reported here as displayed and not as confirmed — neither claimed nor denied.
Not disclosed. Lighter You states only that it is "[n]ot available in all 50 states" and names no state anywhere
The single sentence Lighter You publishes about geography is in its footer disclaimer: "Not available in all 50 states. Please visit our website for full details, applicable restrictions, and important drug safety information." That sentence is itself printed on the website, so the instruction is circular. Searched across the whole client bundle on 2026-08-07, no state name appears anywhere — not as an exclusion list, not as a coverage list, not in the FAQ. The how-it-works copy does acknowledge that a clinician conducts "a synchronous audio or video visit when required by applicable state law", so the company knows state rules vary; it simply does not say which states they are. `statesExcluded` is therefore empty because nothing has been disclosed, not because coverage has been verified as complete. Nothing here was checked against a state board of pharmacy, and no pharmacy is named to check.
A search of the 113 warning letters issued to telehealth firms in the September 9, 2025, February 20, 2026 and June 8, 2026 enforcement waves — matched on full company name rather than substring, because a substring match attaches one company’s regulatory history to another — returns no entry for Lighter You (Lighter You, LLC). That is a statement about those three waves as of August 2026, not a claim that no action exists anywhere.
Assessment
What holds up, and what does not
What holds up
The intake is the best thing here. It screens per ingredient, not per programme — its own rules include "Not eligible for sermorelin under age 25" and separate sermorelin exclusions for elevated IGF-1 and elevated prolactin.
It also disqualifies for uncontrolled diabetes above 10% A1C, routine opiate use, binge drinking and thyroid medication, each mapped to a named ingredient rather than a blanket refusal.
The compounding disclaimer is correct and sits in the footer of every page: FDA "does not evaluate compounded products for safety, effectiveness, or quality."
The how-it-works copy concedes that a synchronous audio or video visit is required where state law demands one, rather than implying a form is always enough.
Cold-chain shipping is stated as included, along with dietitian visits and care coaching, so the programme fee is not obviously a medication-only price.
The FAQ answer on medications is honest about the range offered and attributes prescribing to a licensed provider after clinical evaluation.
What does not
It sells "science-backed peptides" and names none. "Sermorelin", "NAD" and "glutathione" appear zero times in the entire published site.
The "Women's Health" button resolves to the same intake product ID as the peptides programme — the NAD+ and sermorelin questionnaire.
No testing disclosure of any kind: "tested", "sterile", "USP", "potency" and "certificate of analysis" occur zero times across 495,437 characters.
The homepage FAQ promises "a 30-day satisfaction guarantee." The refund policy says "IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION" outside medical disqualification.
A slider returns "Weight you could lose: 48 lbs" for a 220 lb input — about 22% of body weight — with no drug, dose, time period or source attached.
It will not name a state. The only geographic statement is "[n]ot available in all 50 states. Please visit our website for full details" — printed on the website.
Verdict
The bottom line
Lighter You has built a careful clinical intake and wrapped it in a website that tells you almost nothing true about what you are buying. The screening behind the button is real — it refuses sermorelin under 25, refuses it again for elevated IGF-1 or prolactin, and handles each ingredient separately — and that is more clinical thought than most of this category shows. Everything in front of the button is the opposite. A formulary of at least eight compounded ingredients is sold as four words on a card. Not one molecule is named. Nothing is published about testing. No state is named. A satisfaction guarantee is advertised on one page and denied on another. And the button marked Women's Health goes to the NAD+ questionnaire. If you are considering this, the honest advice is that you cannot evaluate it from the outside — which is a finding about the company rather than about the medicine.
Opens www.lighteryou.co. A link is not a recommendation to take anything.
A claim with no noun in it
Here is the entire published case for Lighter You's peptide programme, quoted in full: "Science-backed peptides for energy, recovery, and healthy aging."
That is it. There is no product page. There is no molecule named on the card, in the FAQ, in the footer, or in the terms. Searched across the 495,437-character bundle that renders every route of the site on August 7, 2026, the strings "sermorelin", "NAD" and "glutathione" occur zero times each. The FAQ's answer on what is offered gets as specific as "targeted peptide therapies".
So a reader is asked to accept "science-backed" about an unnamed set of molecules. That is not a claim anyone can check, and being uncheckable is worse than being wrong — a wrong claim can at least be corrected.
The molecules are knowable, though, and it is worth showing the working because the method is the point.
Lighter You's product cards do not link to pages; they link to `/go?product=peptides`. The small JavaScript chunk behind that route contains a hard-coded map from each product name to a checkout URL. For `peptides` it points to `shop.lighteryou.co/intake?productId=UHJvZHVjdDoxNzg=`, and that identifier is base64 for "Product:178". Asking the platform's own public template API what Product:178 is returns an intake called "Metabolic and Cellular Optimization Initial Intake", carrying the program code `nad_sermorelin`.
And the intake enumerates the formulary itself, because it has to — it asks which of these you are allergic to, and which you have recently taken. The list: NAD, sermorelin, B12/B12-MIC, methylene blue, glutathione, L-carnitine, Lipo-C, and Lipo-Mino-Mix-C.
Eight ingredients. Four words of marketing copy.
What the evidence says about the three that matter
Sermorelin. A growth-hormone-releasing hormone analogue, the 1-29 fragment, which does prompt the pituitary to release growth hormone. That mechanism is real and is why the molecule existed, largely as a diagnostic agent. As of August 2026, a PubMed search for sermorelin filtered to randomised controlled trials returns 19 records, and the most recent was published in 2005 — a study of a PEG-conjugated GHRH analogue measuring growth hormone stimulation in healthy young and elderly subjects. 1 Every one of the nineteen measures GH secretion, growth in children, or a diagnostic response. None measures energy, recovery or healthy aging in healthy adults. ClinicalTrials.gov lists 27 sermorelin studies. 2
NAD+. As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" combined with an injected route and filtered to randomised controlled trials returns exactly one record: a 2026 placebo-controlled trial in heart failure caused by ischaemic cardiomyopathy. 3 Worth noting in passing that NAD+ is a dinucleotide rather than a peptide, so the heading "Science-backed peptides" is the wrong category for it.
Glutathione. A tripeptide, so at least the heading fits. As of August 2026, a PubMed search for glutathione with subcutaneous, filtered to randomised trials, returns nine records — of which four are veterinary studies in dairy cattle and goats, and in the other five glutathione is a blood marker somebody measured rather than a drug somebody injected. 4 None tests injected glutathione as an intervention in healthy adults.
Three molecules, and between them one randomised injected-route trial, in cardiology patients, plus a sermorelin literature that stopped twenty-one years ago.
The intake is better than the website
This is the genuinely surprising part, and it deserves its own section because it cuts against everything above.
The questionnaire behind that button is not a formality. It performs per-ingredient disqualification, not per-programme. Its own rules include a hard age floor — "Not eligible for sermorelin under age 25" — and separate sermorelin exclusions for elevated IGF-1 and elevated prolactin, which are precisely the two markers a clinician should care about before stimulating the growth-hormone axis. There are further ingredient-specific refusals for uncontrolled diabetes above 10% A1C, routine opiate use, binge drinking as defined by CDC guidelines, and thyroid medication. Glutathione is separately refused for asthma or COPD. Methylene blue is refused alongside serotonergic medications.
Somebody with clinical training built that. It is more careful than the screening on several better-known companies, and it is invisible to anyone who has not decoded a base64 product ID.
Which produces the strange shape of this review: the medicine appears to be handled with more care than the marketing, and the buyer can only see the marketing.
Two things that do not survive being read side by side
The guarantee. The homepage FAQ, under "Can I cancel anytime?", says: "Yes. Membership is month-to-month with a 30-day satisfaction guarantee."
The cancellation and refund policy, on the same domain, says: "Other than cancellation due to medical disqualification, IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES." The capitals are Lighter You's. The only refund the policy allows is for disqualification by a provider, and cancellation requires 72 hours' notice before the billing date or you are charged for another cycle.
A satisfaction guarantee that returns no money in any circumstance where you are merely dissatisfied is not a satisfaction guarantee. Both sentences are live.
The button. In the redirect map, `womens-health` resolves to Product:178 — the same identifier as `peptides`, the NAD+ and sermorelin intake. There is no women's-health template behind the women's-health card. (For completeness: `mens-health` resolves to Product:168, whose template is named "ED Initial Intake".)
That is a wiring fault rather than a claim, and it may be fixed by the time you read this. It is recorded here with its date because it is exactly checkable: follow the button and see where you land.
What cannot be evaluated from outside
Two absences close this out, and both were measured rather than inferred.
There is no testing disclosure. Across the whole bundle, "tested", "sterile", "USP", "potency", "purity", "certificate of analysis", "COA", "503A" and "503B" occur zero times. Lighter You never states whether its preparations come from a 503A pharmacy or a 503B outsourcing facility, and it never names the pharmacy — "pharmacy" occurs twice in the entire site, both times as "partner pharmacy". Its pages carry a LegitScript seal under certificate id 51449551; LegitScript's public checker is reCAPTCHA-gated and returned no record when queried, so that seal is reported here as displayed and not as confirmed.
And there is no state list. The only geographic statement anywhere is the footer's "Not available in all 50 states. Please visit our website for full details, applicable restrictions, and important drug safety information" — an instruction to visit the website, printed on the website. No state name appears anywhere in the bundle.
Lighter You is not obviously doing anything wrong. That is rather the difficulty: from the outside, there is no way to establish that it is doing anything right either, beyond an intake form you have to reverse-engineer a button to find.
Questions
Frequently asked questions
Which peptides does Lighter You actually sell?▾
The site never says, and that is the finding. Its only description is "Science-backed peptides for energy, recovery, and healthy aging," and the words sermorelin, NAD and glutathione appear zero times across the whole published site. The formulary can be established from Lighter You's own funnel: the peptides button redirects to an intake whose template is called "Metabolic and Cellular Optimization Initial Intake" and whose program code is nad_sermorelin, and that intake's own eligibility rules name its ingredients — NAD, sermorelin, B12/B12-MIC, methylene blue, glutathione, L-carnitine, Lipo-C and Lipo-Mino-Mix-C. Read on August 7, 2026.
Is there evidence behind "science-backed peptides"?▾
Not for the outcomes advertised. Sermorelin: as of August 2026, 19 randomised trials in PubMed, the newest from 2005, all measuring growth hormone secretion, growth in children, or a diagnostic response — none measuring energy, recovery or healthy aging in healthy adults. Injectable NAD+: one randomised injected-route trial, in heart failure caused by ischaemic cardiomyopathy. Injected glutathione: nine randomised trials match the route, four of them veterinary, and in the rest glutathione was measured rather than injected. The mechanisms these molecules act on are real. The outcomes on the card have not been tested.
Why isn't Lighter You on the pricing side of this network?▾
Because there is no price to check. Its cards read "Starting at $169", "Starting at $145" and, for two of five programmes, "Membership + Medication Cost" — a format rather than a figure. A banner advertises "Starting at $99", $70 below the weight-loss card on the same page, and nothing states which is a first month and which is ongoing. Across the whole site, "per month", "/mo", "first month" and "intro" occur zero times. The route to a real number is gated behind account creation, and the intake asks for a legal name and phone number before showing anything. A cost review would have to invent the number it exists to verify.
Does the "Women's Health" button work?▾
It goes somewhere, but not where the label says. In Lighter You's own redirect map, read on August 7, 2026, the womens-health product resolves to the same intake identifier as the peptides programme — Product:178, the "Metabolic and Cellular Optimization" questionnaire for NAD+ and sermorelin. There is no separate women's-health template behind it. For completeness, the mens-health card resolves to Product:168, whose template is named "ED Initial Intake". This is a wiring fault rather than a claim, and it may be corrected; the check is to follow the button and see where you land.
Is there really a 30-day satisfaction guarantee?▾
Two Lighter You pages disagree. The homepage FAQ says "[m]embership is month-to-month with a 30-day satisfaction guarantee." The cancellation and refund policy says, in capitals, "[o]ther than cancellation due to medical disqualification, IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES." The only refund the policy contemplates is disqualification by a provider, and cancellation must reach the company at least 72 hours before the billing date or another cycle is charged. Both pages were live on August 7, 2026.
What does Lighter You publish about testing or the pharmacy?▾
Nothing, in both cases, and this was measured. Across the 495,437-character bundle that renders the site, the strings "tested", "sterile", "USP", "potency", "purity", "certificate of analysis", "COA", "503A" and "503B" occur zero times. The word "pharmacy" occurs twice, both times as "partner pharmacy". So there is no named pharmacy, no stated regulatory category for the preparations, no testing standard and no lot report. The footer does carry a correct disclaimer that FDA "does not evaluate compounded products for safety, effectiveness, or quality" — which describes what has not been checked, not what has.
Has Lighter You had an FDA warning letter?▾
No match was found. On August 7, 2026 the 113-letter telehealth warning-letter roster was screened for "Lighter You", "lighteryou" and "OpenLoop" — the last being the telehealth partner its footer links to — on full company names rather than fragments. None appears. As always, the roster covers the telehealth enforcement waves rather than every letter FDA has issued, and the absence of a letter is not a clean inspection record. In this case there is an extra limit: the pharmacy that would be inspected is not named.
Glossary
Key terms
503A compounding pharmacy
A state-licensed pharmacy preparing a medicine against a prescription for a named patient. Compounded preparations are not FDA-approved and FDA does not review them for safety, effectiveness or quality. Lighter You never states which category its preparations come from — "503A" and "503B" appear nowhere on its site.
GHRH analogue
A molecule shaped like growth-hormone-releasing hormone, which prompts the pituitary to release growth hormone rather than supplying it directly. Sermorelin is the 1-29 fragment. Elevated IGF-1 and prolactin are the markers that make stimulating that axis inadvisable — which is why Lighter You's intake screens for both.
Lipotropic injection
An injected blend of methionine, inositol and choline, usually with vitamin B12 — sold here as B12-MIC, Lipo-C and Lipo-Mino-Mix-C. The individual compounds have literatures of their own; the blends as sold have no registered randomised trial.
Certificate of analysis
A lot-specific laboratory report stating what was tested and what the results were. A seller describing a testing programme and a seller publishing a certificate you can read are making different claims. Lighter You makes neither.
Per-ingredient screening
An intake that refuses one component of a programme while allowing the others, rather than accepting or rejecting a patient wholesale. Lighter You's questionnaire does this — declining sermorelin for a patient under 25 or with raised IGF-1 while leaving the rest of the formulary available.
Method
How we checked this
Claims read first-party
Every quoted claim was read off Lighter You's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Sources
References
1.Munafo A, Nguyen TX, Papasouliotis O, et al. (2005). Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.. European journal of endocrinology 153(2):249-56. https://pubmed.ncbi.nlm.nih.gov/16061831/
3.Yu X, Xu J, Cao J (2026). Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.. American journal of cardiovascular drugs : drugs, devices, and other interventions 26(1):97-106. https://pubmed.ncbi.nlm.nih.gov/40954388/
5.Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
6.Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. The New England journal of medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
7.Novo Nordisk A/S; Eli Lilly and Company (2026). STEP 1, NCT03548935 — phase 3, completed, enrolment 1,961; and SURMOUNT-1, NCT04184622 — phase 3, completed, enrolment 2,539. Both read 2026-08-07. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.